What is T3?
T3 (liothyronine) is the synthetic form of triiodothyronine, the active thyroid hormone. While the thyroid mainly produces the storage hormone T4 that the body must first convert to T3, liothyronine acts immediately and directly. It raises basal metabolic rate and speeds up metabolism - used in research contexts for fat burning.
This information is for research and educational purposes only. No medical advice.
Comparison
T3, T4 and other paths
Thyroid hormones and one compound with a different path to energy use, as described in the TPD lexicon. Tap a card to open its entry.
T4 is the storage form and is converted to T3 in the body, T3 acts directly. About a third of the amount gives the same TSH suppression. 28
How it works
T3 binds thyroid hormone receptors in virtually every cell and raises the metabolic rate - cells burn more energy. That markedly increases calorie consumption at rest. The catch: T3 is not selective for fat. At too high a dose the body also burns muscle tissue. On top of that, the body's own thyroid production is suppressed.
Where it acts
Where T3 acts
Tap a point or a card. Colour = thyroid hormone receptor, grey = observed in studies.
Targets in the ChEMBL database8
Compound CHEMBL1201119: one recorded mechanism, agonist with direct binding to the human receptor.
- Gene
- THRA, THRB
- UniProt
- P10827, P10828
- ChEMBL
- CHEMBL2111462
- Action
- Agonist, direct binding
Dosing
Dosing
Dosing, titration and syringe
Loading the dosing information …
- Getting started and stepping up, drawn as a staircase
- Units on the U-100 syringe for every step
- How long one vial lasts
What the research shows
The Celi study (J Clin Endocrinol Metab, 2011) compared liothyronine directly with levothyroxine (T4) and showed that T3, at an equivalent dose, led to greater weight loss and a better lipid profile, with no differences in cardiac function or insulin sensitivity. That confirms the direct metabolic effect.
Study results
What the trials measured
Interactive: switch tabs, tap points, show or hide arms. Arms are named relative to each other, no dosing advice.
Weight and blood lipids with T3 instead of T41
Difference from the T4 phase, same TSH, in percent
14 people with hypothyroidism, 6 weeks each of T3 and T4 in random order, same target TSH. Weight calculated by us from the mean values, blood lipids as mean values in the abstract. HDL, heart rate, blood pressure, exercise capacity and insulin sensitivity did not differ.
How fast T3 comes and goes34
Hours after a single dose, healthy people
Heart rate rose briefly 5 hours after the dose. TSH reached its lowest point after 12 hours and stayed below baseline for 2 to 3 days. Depending on the chosen time points a longer half-life results, the US label gives a biological half-life of about 2.5 days.
Antidepressant with or without T35
153 adults, 8 weeks, share in percent
No difference between the groups. The authors do not support routinely adding T3 at the start of treatment.
Research status
Where the research stands
Liothyronine has been approved since 1956 and the registry lists about 900 trials with it. Here is a selection, including all trials whose results appear above. As of 26 Oct 2026. 9
- Preclinical Action on the thyroid hormone receptor
- Phase 1 no registered trial
- Phase 2 3 trials, 3 completed
- Phase 3 3 trials, 2 completed
- Approval in the USA since 1956
Show all 7 phase 2, 3 and 4 trials on a timelineHide timeline
NCT00106119 · 18 participants, started Mar 2005, primary endpoint reached Nov 2013. Tests several agents.
Registry entry ↗ · Results: Celi et al., Journal of Clinical Endocrinology and Metabolism, 2011, Celi et al., Clinical Endocrinology, 2010
NCT03098433 · 22 participants, started Oct 2017, primary endpoint reached Jun 2019. Tests several agents.
Registry entry ↗ · Results: Chen et al., Frontiers in Endocrinology, 2022
DOT3HF-HFrEF · NCT04112316 · 28 participants, started Feb 2020, primary endpoint reached Oct 2023.
Registry entry ↗ · Results not yet in PubMed
TRICC-2 · NCT02320669 · 220 participants, started Nov 2014, primary endpoint reached Oct 2019.
Registry entry ↗ · Results not yet in PubMed
LEVOLIO · NCT03053115 · 160 participants, started Mar 2017, primary endpoint reached Sept 2021. Tests several agents.
Registry entry ↗ · Results not yet in PubMed
T3-4-Hypo · NCT05682482 · 600 participants (planned), started Oct 2022, primary endpoint planned Jan 2028. Tests several agents.
NCT00208702 · 153 participants, started Sept 1996, primary endpoint reached Jul 2003. Tests several agents.
Registry entry ↗ · Results: Garlow et al., Journal of Psychiatric Research, 2012
Bar: start to primary endpoint (planned for running trials). Green = completed, blue = progress until 26 Oct 2026.
Side effects
- Muscle loss: at too high a dose T3 also burns muscle - so in research it is often combined with anabolics to protect muscle.
- Heart: palpitations, raised pulse, arrhythmia risk on overdose.
- Thyroid suppression: your own production winds down - hence the slow taper.
- Sweating, nervousness, feeling hot.
Storage
Store dry and protected from light. Out of reach of children.